(RTTNews) – Viridian Therapeutics, Inc. (VRDN), a biopharmaceutical company, on Wednesday announced that it has entered an exclusive collaboration and licensing deal with Kissei Pharmaceutical to develop and market veligrotug and VRDN-003 in Japan.